DETROIT and MENLO PARK, Calif. – (Sept. 22, 2022) – Holly Ford Wellness , one of the nation’s leading academic medical centers recognized for excellence in clinical care, research and education, and GRAIL, LLC , a healthcare company whose mission is to detect cancer early when it can be cured, today announced Henry Ford Health as the first healthcare provider within Michigan to offer Galleri® , GRAIL’s Multi-Cancer Early Detection (MCED) blood test. Henry Ford is among an early group of healthcare providers in the U. S. to offer this MCED test.
“We are entering an era of unprecedented ability to detect cancer at its earliest stages, which may ultimately help save many lives, ” said Adnan Munkarah, M. D. , Chief Clinical Officer at Holly Ford Wellness. “Diagnosing and treating malignancy at an earlier stage often leads to more favorable outcomes. We are excited to provide this MCED blood check, which study shows can detect a cancer signal shared across more than 50 types of cancer through a single blood draw. ”
The Galleri test is intended for use in those who are in an elevated risk associated with cancer, such as individuals ages 50 or older. Some younger people may also have an elevated risk of cancer, which is why Henry Kia is making the Galleri test available to patients who are usually 22 years or older, have no history of malignancy or have been cancer-free at least three years, and are not currently pregnant.
“We believe that multi-cancer earlier detection tests like Galleri are the new front on the war against cancer and will enable us to dramatically increase malignancy detection from screening within the population, with the goal associated with improving public health, ” said Bob Ragusa, Main Executive Official at GRAIL. “We are capable to work with Henry Ford Health in adding Galleri as a complement in order to U. H. guideline-recommended cancer screenings. ”
Galleri MCED test may detect many cancers that are not commonly screened with regard to today to allow for earlier treatment, and can be incorporated into a routine healthcare visit. If a cancer signal is found, the results can point to where in the body the cancer is coming from. This may help health care providers guide next steps.
“Routine malignancy screenings remain essential regarding early detection, ” stated Ben Movsas, M. Deb. , Medical Director of Henry Ford Health Cancer . “But a MCED blood test can be used in addition to guideline-recommended cancer screenings, such as mammography, colonoscopy, prostate-specific antigen or even cervical malignancy screening. In a clinical study, the check also detected some cancer types, this kind of as pancreatic, ovarian plus esophageal, that will currently lack routine recommended screening guidelines. This can provide a way to identify cancers earlier that are usually often not detected until a later stage. ”
All cells in your body release DNA into the bloodstream, but DNA from malignancy cells is different from the particular DNA associated with healthy tissues. The Galleri test looks at the DNA in a patient’s bloodstream to determine if any of it may have come from cancer cells. In a clinical research , the particular Galleri test demonstrated the ability in order to detect the shared transmission from a lot more than fifty types of cancer, more than 45 of which lack suggested screening assessments today. Final results from the first PATHFINDER study , an interventional study that examined how well a good MCED check can become integrated into medical practice, were presented from the European Society intended for Medical Oncology (ESMO) Congress 2022 and demonstrated Galleri’s performance was consistent with findings through previous observational and case-controlled studies, underscoring the potential real-world ability associated with Galleri to find a lot more cancers within earlier stages.
“For many people, routine malignancy screenings are a part of the regular care they receive from their primary care physician, ” said Dan Passerman, M. O. , Chair associated with Family Medicine at Holly Ford Wellness. “The ability to include this test inside a routine check out, and in order to obtain actionable health information as a result, will help individuals protect their health in a very meaningful plus convenient way. ”
Because the test is not really currently covered by insurance, the Galleri MCED check is an out-of-pocket cost. Patients may be eligible to participate within the interventional PATHFINDER 2 study , which usually is evaluating the implementation and performance of Galleri in a clinical treatment setting. The particular study is currently enrolling individuals who meet the particular eligibility requirements, which include:
- 50 many years or old and receive care with Henry Kia Health.
- Have never been diagnosed along with cancer or have already been cancer-free a minimum of three yrs.
- Are not participants in previous or ongoing GRAIL sponsored studies.
Henry Ford team members and their dependents who are enrolled in the Health Alliance Plan (HAP) of Michigan insurance plan may be eligible for a test at no cost.
Galleri is obtainable by physician order only. Those who might be interested in the Galleri test should consult with their Henry Ford primary care doctor to determine whether the test is appropriate for them.
To learn more about the Galleri test on Henry Kia Health, go to henryford. com/cancerbloodtest .
About Henry Ford Health
Serving communities throughout Michigan plus beyond, Holly Ford Health is committed to partnering with individuals and members along their own entire health journey. Henry Ford Health provides a full continuum of services – from primary and preventative care, to complex and specialty care, wellness insurance, a full suite of home health offerings, virtual care, pharmacy, eye treatment and other healthcare retail.
It is one of the nation’s top academic healthcare centers, acknowledged for scientific excellence in cancer care, cardiology plus cardiovascular surgery, neurology and neurosurgery, orthopedics and sports medicine, plus multi-organ transplants. Consistently ranked among the top five NIH-funded institutions within Michigan, Holly Ford Wellness engages in a lot more than 2, 000 analysis projects annually. Equally committed to educating the next generation associated with health professionals, Henry Kia Health trains greater than 4, 000 medical students, residents and fellows every year across 50+ accredited programs.
With more than 33, 000 valued team members, Henry Ford Wellness is furthermore among Michigan’s largest and most diverse employers, including nearly 6, 000 physicians and researchers from the particular Henry Ford Medical Group, Henry Kia Physician Network and Jackson Health System.
The health system is led by President and CEO Robert G. Riney plus serves a growing number of customers throughout 250+ locations throughout The state of michigan including five acute treatment hospitals, two destination facilities for complicated cancer and orthopedics plus sports medicine care, 3 behavioral wellness facilities, main care and urgent care centers.
GRAIL is the healthcare company whose mission is to detect cancer early, in order to may be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect plus identify multiple deadly cancer types earlier. The company is using the power associated with next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science plus data science to enhance the scientific understanding of malignancy biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in Menlo Park, CA with areas in Washington, D. C., North Carolina, and the United Kingdom. GRAIL, LLC, is a subsidiary of Illumina, Inc. (NASDAQ: ILMN) currently held separate through Illumina Incorporation. under the particular terms of the Interim Measures Order of the Western Commission dated 29 October 2021.
For more information, visit grail. com .
The earlier that will cancer will be detected, the higher the chance of successful outcomes. The Galleri multi-cancer early recognition test can detect signals across over 50 forms of cancer, because defined by the American Joint Committee upon Cancer Staging Manual, through a routine bloodstream draw. When a cancer signal is recognized, the Galleri test predicts the cancer signal origin, or where the cancer is located in the body, with high accuracy in order to help manual the next steps to diagnosis. The Galleri test requires a prescription from a licensed healthcare provider and should be used in addition to recommended cancer screenings like mammography, colonoscopy, prostate-specific antigen (PSA) test, or even cervical malignancy screening. It is intended for use within people with a good elevated risk of cancer, such since those aged 50 or older.
With regard to more info about Galleri, visit galleri. com .
Important Galleri Safety Information
The Galleri test is usually recommended to get use in adults along with an raised risk pertaining to cancer, for example those older 50 or even older. The particular Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests suggested by a healthcare provider. Galleri is intended to identify cancer indicators and predict where in the body the malignancy signal is located. Use associated with Galleri is definitely not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider within the context of medical background, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Transmission Detected” needs confirmatory diagnostic evaluation simply by medically established procedures (e. g., imaging) to confirm cancer.
If cancer can be not confirmed with further testing, it could mean that cancer is certainly not present or testing was insufficient to detect cancer, which includes due to the malignancy being located in a different part of the entire body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not really detected whenever cancer will be present) check results do occur. Rx only.
GRAIL’s clinical laboratory is certified under the particular Clinical Laboratory Improvement Amendments of 1988 (CLIA) plus accredited by the College of American Pathologists. The Galleri test was developed, and its overall performance characteristics had been determined by GRAIL. The Galleri test has not been cleared or approved by the U. T. Food and Drug Administration. GRAIL’s clinical lab is regulated under CLIA to perform high-complexity testing. The particular Galleri test is supposed meant for clinical purposes.
MEDIA CONTACTS :
For Holly Ford Health
Jeff Adkins / 586. 307. 2027 / [email protected] org
GRAIL Investor Relations